Investors News Year 2022 2021 2020 2019 2018 2021 BioGraphene 1/4/21 2021 BioGraphene 1/4/21 BioGraphene Signs Collaborative Research Agreement with Samsung Medical Center for the Efficacy Study of Graphene Quantum Dots in Alzheimer’s Disease Read More 2020 BioGraphene 10/1/20 2020 BioGraphene 10/1/20 BioGraphene Appoints Yongseok Choi to New CEO Read More 2020 BioGraphene 5/7/20 2020 BioGraphene 5/7/20 BioGraphene Announces Publication in Science Advances on Graphene Quantum Dots’ Role Against Inflammatory Response in Colitis Read More 2019 BioGraphene 11/13/19 2019 BioGraphene 11/13/19 BioGraphene Signs Collaboration Agreement with NICHD to Initiate Efficacy Studies of Graphene Quantum Dots in Lysosomal Storage Disorders Using Animal Models Read More 2019 BioGraphene 11/1/19 2019 BioGraphene 11/1/19 BioGraphene Signs Collaborative Research Agreement with Seoul National University for the Efficacy Study of Graphene Quantum Dots in Glomerulonephritis Read More Newer Posts Older Posts
2021 BioGraphene 1/4/21 2021 BioGraphene 1/4/21 BioGraphene Signs Collaborative Research Agreement with Samsung Medical Center for the Efficacy Study of Graphene Quantum Dots in Alzheimer’s Disease Read More
2020 BioGraphene 10/1/20 2020 BioGraphene 10/1/20 BioGraphene Appoints Yongseok Choi to New CEO Read More
2020 BioGraphene 5/7/20 2020 BioGraphene 5/7/20 BioGraphene Announces Publication in Science Advances on Graphene Quantum Dots’ Role Against Inflammatory Response in Colitis Read More
2019 BioGraphene 11/13/19 2019 BioGraphene 11/13/19 BioGraphene Signs Collaboration Agreement with NICHD to Initiate Efficacy Studies of Graphene Quantum Dots in Lysosomal Storage Disorders Using Animal Models Read More
2019 BioGraphene 11/1/19 2019 BioGraphene 11/1/19 BioGraphene Signs Collaborative Research Agreement with Seoul National University for the Efficacy Study of Graphene Quantum Dots in Glomerulonephritis Read More
